Reference:
Thompson Coon J, Hoyle M, Green C, Liu Z, Welch K, Moxham T, Stein K. Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: A systematic review and economic evaluation. Health Technology Assessment 2010;14(2): 1-184.